Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
For the fiscal year ending March 2025, Blue Jet Healthcare's projected total assets are ₹1,418.0, with total liabilities also at ₹1,418.0. Reserves are expected to be ₹1,098.0. For the fiscal year ending March 2026, total assets are projected to be ₹1,641.0, with total liabilities at ₹1,641.0 and reserves at ₹1,325.0. Cash flow from operating activities is projected to increase from ₹46.0 in March 2025 to ₹334.0 in March 2026. Free cash flow is expected to move from a negative ₹34.0 in March 2025 to a positive ₹115.0 in March 2026.
Blue Jet Healthcare will hold its 58th Annual General Meeting on September 21, 2026, conducted virtually via video conferencing. The agenda includes adopting financial statements for the year ended March 31, 2026, declaring a dividend of ₹1.20 per equity share, and considering the re-appointment of statutory auditors and key management personnel. The record date for the dividend is September 14, 2026.
Over the last 5 years, Blue Jet Healthcare has shown a compounded sales growth of 14% and a compounded profit growth of 11%. However, for the Trailing Twelve Months (TTM) period, sales growth has declined by 28%, and profit growth has decreased by 34%.
As of September 18, 2026, the daily trend indicators suggest a bearish Supertrend at 608.2, with the closing price at ₹575.25. The weekly trend, however, shows a bullish Supertrend at 448.4. The stock has experienced a 1-year return of -16% and a year-to-date return of 9%.
For the fiscal year 2025-26, Blue Jet Healthcare reported a reduction in Scope 1 and Scope 2 greenhouse gas emissions to 32,138.47 tCO2e from 34,885.47 tCO2e in the previous fiscal year. The company maintained a zero Lost Time Injury Frequency Rate and zero fatalities. Approximately 90% of the company's turnover is derived from exports.
As of 18 Sept 2026, 03:30 pm
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹293.11 crore | ₹234.67 crore | ₹192.41 crore | ₹165.48 crore | PEAK₹354.76 crore |
| Finance Costs | ₹66 lakh | ₹58.30 lakh | ₹33.90 lakh | PEAK₹4.63 crore | ₹69 lakh |
| Other Expenses | ₹37.81 crore | PEAK₹42.72 crore | ₹33.60 crore | ₹34.11 crore | ₹33.44 crore |
| Profit Before Tax | ₹105.95 crore | ₹87.15 crore | ₹53.78 crore | ₹68.73 crore | PEAK₹122.86 crore |
| Tax Expense | ₹27.68 crore | ₹22.81 crore | ₹13.61 crore | ₹16.59 crore | PEAK₹31.69 crore |
| Profit Loss For Period | ₹78.26 crore | ₹64.34 crore | ₹40.17 crore | ₹52.14 crore | PEAK₹91.17 crore |
Exchange disclosures and regulatory announcements for Blue Jet Healthcare.
Blue Jet Healthcare Limited announced on August 19, 2026, that its 58th Annual General Meeting for the fiscal year 2025-26 will be held virtually via video conferencing on September 21, 2026, at 11:00 AM IST. The company published newspaper advertisements in Financial Express and Navshakti to inform shareholders about the dispatch of the annual report and details regarding the E-voting facility. Company Secretary Sweta Poddar signed the intimation to comply with SEBI Listing Regulations, confirming the meeting's schedule and remote participation mode.
Blue Jet Healthcare Limited will hold its 58th Annual General Meeting on September 21, 2026, at 11:00 AM IST via video conferencing. The board has recommended a final dividend of ₹1.20 per equity share for the financial year ended March 31, 2026, with a record date of September 14, 2026. The meeting will consider the re-appointment of M/s. KKC & Associates LLP as statutory auditors for a second five-year term and the re-appointment of Mr. Akshay Bansarilal Arora as Whole-Time Director and Executive Chairman for a five-year term from April 13, 2027, to April 12, 2032, and Mr. Shiven A. Arora as Managing Director for the same period.
Blue Jet Healthcare Limited will hold its 58th Annual General Meeting on September 21, 2026, via video conference. Agenda items include adopting audited standalone financial statements for FY ended March 31, 2026, declaring a dividend of Rs 1.20 per share, re-appointing Mr. Naresh Suryakant Shah as Executive Director (tenure Dec 31, 2025 to Dec 31, 2027), re-appointing M/s. KKC & Associates LLP as Statutory Auditors (tenure Sept 21, 2026 to Sept 30, 2031), and re-appointing Mr. Akshay Bansarilal Arora as Whole-Time Director and Executive Chairman and Mr. Shiven A. Arora as Managing Director, both for a five-year term starting April 13, 2027.
Blue Jet Healthcare Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the BSE and NSE on August 18, 2026. The filing discloses that the company achieved a reduction in Scope 1 and Scope 2 greenhouse gas emissions from 34,885.47 tCO2e in FY 2024-25 to 32,138.47 tCO2e in FY 2025-26, while maintaining zero Lost Time Injury Frequency Rate (LTIFR) and zero fatalities. Additionally, the report confirms reasonable assurance obtained from TÜV India Pvt Ltd for BRSR Core indicators and details that approximately 90% of the company's turnover is derived from exports.
Blue Jet Healthcare Limited announced that its 58th Annual General Meeting will be held on September 21, 2026, at 11:00 A.M. IST via video conferencing, with a record date of August 25, 2026, for a final dividend of ₹1.20 per share (60% of the face value). The company also disclosed that the National Company Law Tribunal ordered the transfer of shares worth approximately ₹49.13 million to the Investor Education and Protection Fund due to unclaimed status as of August 5, 2026.
Blue Jet Healthcare Limited held an earnings call on August 3, 2026, to discuss financial results for the quarter ended June 30, 2026. The company reported revenue of INR293 crores and EBITDA of INR98 crores, with improvements driven by the PI vertical. Key strategic initiatives include progress on the Vizag project, with an investment of approximately INR1,000 crores over three years, and the Hyderabad R&D center expected to become operational in August 2026. The company also noted INR210 crores invested in the Mahad backward integration project for contrast media intermediates, with an additional INR40 crores committed.
Blue Jet Healthcare Limited published its unaudited standalone financial results for the quarter ended June 30, 2026, on August 4, 2026. The results were advertised in the Financial Express and Navshakti newspapers. The full financial results are available on the BSE website and the company's investor relations portal.
Recent market and company developments associated with Blue Jet Healthcare.
Dividend stocks including Kalyan Jewellers, Aarti Industries, and 38 more, are poised to attract investor interest on Friday, September 11. These companies have set record dates for dividend payouts on September 12 and 14.
Axis AMC, PMS, Alternates, Axis brokerage. portfolio management
ICICI Securities, Blue Jet Healthcare, buy, Recommendations
Sensex, Nifty, Stock Price Live Updates: The fresh week began on a positive note for Indian stocks, thanks to softer crude oil prices and stable global markets.
Blue Jet Healthcare's revenue from operations fell 17.4% year-on-year to ₹293 crore, down from ₹355 crore a year earlier.
Q1 Results LIVE Updates: SBI Funds Management, Ather Energy, Inox India, IREDA, DOMS Industries, DLF, Escorts Kubota, CAMS, NOCIL, Nazara Tech, PNC Infra, Torrent Power, UPL, Restaurant Brands Asia, PNC Infra, KIMS, KEI Industries, Jindal Stainless, Ethos, GSK Pharma, Bluejet Healthcare, Kansai Nerolac, JM Financial, Kalpataru, Dhanuka Agritech, Texmaco Rail, are among the companies reporting their earnings today. Results reactions will come from stocks like ITC, Maruti Suzuki, Muthoot Finance, Dixon tech, and many others. Watch this space for all the LIVE Q1 results updates.
Sensex Today | Stock Market Live Updates: We are at the halfway mark of the day's trade, and the markets are trading on a strong footing, holding onto the gains. The Nifty is up over 200 points, rising above 24,600. The Nifty Bank is also higher, jumping over 530 points, rising to 57,600. ITC, Shriram Fin and IndiGo are top gainers.
Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,BLS E-Services,Hero MotoCorp,Jio Financial Services,Anant Raj,Anthem Biosciences,Blue Jet Healthcare,Shipping Corporation of India,KEI Industries,Escorts Kubota
Comprehensive Section Breakdown for Blue Jet Healthcare
Strategic Vision: Manufactures and supplies pharmaceutical and healthcare ingredients globally.
• Specialization in niche chemical segments
• Extensive manufacturing experience in specific product lines
• Backward integration and indigenous sourcing of raw materials
• cGMP compliant facilities and robust regulatory support for CDMO services
Blue Jet Healthcare reported revenue of ₹293.11 crore and net profit of ₹78.26 crore for the first quarter of FY2026‑27, ended 30 June 2026. While both figures marked a sharp improvement from the lows of the previous fiscal year, they remained well below the levels recorded in the same quarter a year ago. The quarter’s performance highlights a recovery in business activity from the mid‑year trough, but the company has not yet returned to its prior‑year peak.
Revenue for the quarter stood at ₹293.11 crore. This was a 24.9% increase from the ₹234.67 crore reported in the fourth quarter of FY2025‑26, and it followed even lower revenue in the second and third quarters of that year. The sequential rise shows a meaningful pickup from the weaker second half of the previous fiscal year.
Compared with the same quarter a year ago, however, revenue fell 17.4% from ₹354.76 crore in Q1 FY2025‑26. The current quarter’s revenue therefore sits between the prior‑year high and the mid‑year troughs of ₹165.48 crore (Q2) and ₹192.41 crore (Q3). Over the five‑quarter period, revenue has fluctuated considerably, with the latest figure representing a partial recovery rather than a return to the earlier peak.
Profit before tax (PBT) was ₹105.95 crore, up 21.6% from ₹87.15 crore in the previous quarter. Other income of ₹15.24 crore contributed to pre‑tax profit. The ratio of PBT to revenue (which includes other income) rose to 36.1% from 34.6% in Q1 FY2025‑26.
Net profit for the quarter was ₹78.26 crore, yielding a net profit margin of 26.7% compared with 25.7% a year earlier. The improvement in both ratios indicates that the company generated more profit per rupee of revenue, even as total revenue declined.
Cost of materials consumed was the largest expense at ₹178.88 crore, representing 61% of revenue. Employee benefit expenses amounted to ₹20.12 crore.
Other expenses fell 11.5% sequentially to ₹37.81 crore from ₹42.72 crore in Q4 FY2025‑26. This decline, alongside higher revenue, supported the rise in pre‑tax profit. On a year‑on‑year basis, other expenses increased from ₹33.44 crore in Q1 FY2025‑26 to ₹37.81 crore.
Finance costs remained low at ₹0.66 crore, little changed from the previous quarter and well below the ₹4.63 crore recorded in Q2 of the prior fiscal year. Depreciation and amortisation expenses were ₹6.71 crore, or 2.3% of revenue.
Net profit of ₹78.26 crore was 21.6% higher than the ₹64.34 crore reported in the preceding quarter, but 14.2% lower than the ₹91.17 crore earned in Q1 FY2025‑26. Basic and diluted earnings per share followed the same pattern, rising to ₹4.51 from ₹3.71 sequentially, while declining from ₹5.26 a year earlier.
The tax expense for the quarter was ₹27.68 crore, resulting in an effective tax rate of 26.1% on pre‑tax profit. This was broadly in line with the 25.8% rate recorded in the same quarter last year.
Blue Jet Healthcare’s first quarter delivered a strong sequential recovery from the lows of the previous fiscal year, with revenue and net profit each rising more than 20% from the prior quarter. However, both the top and bottom lines remained significantly below the year‑ago quarter, with revenue down 17% and net profit down 14%. Profit margins improved year‑on‑year, showing that the company earned more profit per rupee of revenue despite the lower sales volume. The quarter reflects a business that is recovering from a mid‑year trough but has not yet regained its prior‑year scale.
Category: Manufacturing
Develops and manufactures high-purity contrast media intermediates used by pharmaceutical and diagnostic imaging companies worldwide, including intermediates for iodine-based and gadolinium-based contrast agents.
Category: Manufacturing
Manufactures Saccharin Sodium and Insoluble Saccharin for healthcare, pharmaceuticals, animal feed, food, and beverages, complying with major pharmacopoeial standards.
Key Products & Services: Saccharin Sodium • Insoluble Saccharin
Category: B2B Services
Offers protected amino acids, derivatives, and CDMO services for pharmaceutical intermediates and APIs, covering process development to commercialization for NCEs, intermediates, and APIs.
Core Thesis: The company leverages its expertise in niche chemical segments to serve global pharmaceutical and FMCG customers across multiple business areas.
• Manufacturing Excellence: Operates multi-ton, cGMP compliant manufacturing facilities with a focus on efficient project execution and adherence to global best practices. • Innovation and Development: Maintains strong innovation capabilities and invests in ongoing development and small-scale manufacturing for new product lines like amino acid-based derivatives. • Global Reach and Customer Service: Serves over 350 customers across more than 35 countries, ensuring supply chain integrity and confidentiality. • Regulatory Compliance: Ensures robust regulatory support and compliance across its operations and product offerings.